分子别名(Synonym)
IL-27B, IL27B, IL35B
表达区间及表达系统(Source)
Human EBI3 Protein, His Tag (EB3-H51H3) is expressed from E. coli cells. It contains AA Arg 21 - Lys 229 (Accession # Q14213).
Predicted N-terminus: Met
Request for sequence
蛋白结构(Molecular Characterization)
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 25.3 kDa. The protein migrates as 25-26 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE).
内毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
纯度(Purity)
>90% as determined by SDS-PAGE.
制剂(Formulation)
Lyophilized from 0.22 μm filtered solution in 20 mM NaAc, 150 mM NaCl, pH3.5 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
电泳(SDS-PAGE)
Human EBI3 Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
活性(Bioactivity)-ELISA
Immobilized Human IL-27 Protein, Fc Tag, premium grade (Cat. No. IL7-H5254) at 10 μg/mL (100 μL/well) can bind Human EBI3 Protein, His Tag (Cat. No. EB3-H51H3) with a linear range of 0.02-0.625 μg/mL (QC tested).
Protocol
背景(Background)
This gene was identified by its induced expression in B lymphocytes in response Epstein-Barr virus infection. It encodes a secreted glycoprotein belonging to the hematopoietin receptor family, and heterodimerizes with a 28 kDa protein to form interleukin 27 (IL-27). IL-27 regulates T cell and inflammatory responses, in part by activating the Jak/STAT pathway of CD4+ T cells.